Is Prothena Corporation plc (PRTA) Overvalued?
We dive into why Prothena Corporation plc (PRTA) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer’s disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer’s disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer’s disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Commentary & Analysis
Why Prothena Corporation plc’s (PRTA) Stock Is Down 5.50%
As of Friday, July 10, Prothena Corporation plc’s PRTA share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Prothena Corporation plc’s (PRTA) Stock Is Up 5.06%
As of Thursday, July 02, Prothena Corporation plc’s PRTA share price has surged by 5.06%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Prothena Corporation plc’s (PRTA) Stock Is Up 5.29%
As of Friday, June 26, Prothena Corporation plc’s PRTA share price has surged by 5.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Prothena Corporation plc’s (PRTA) Stock Is Up 5.68%
As of Tuesday, June 23, Prothena Corporation plc’s PRTA share price has surged by 5.68%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | PRTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $504.1 | $282.4 | 37% |
|
| Shares Out (Mil) | 52.1 | 54.0 | 48% |
|
| Institutional Ownership | 79.2% | 93.1% | 48% |
|
| Float (Mil) | 34.9 | 42.2 | 39% |
|
| Beta | -0.35 | 0.94 | 2% |
|
| Avg Daily Volume (000s) | 334 | 482 | 54% |
|
| Price Change (52-week) |
19.6% | 59.9% | 63% |
|
| Growth | PRTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 60.9% | 14.1% | 97% |
|
| Net Income (5yr) | (17.0%) | (10.1%) | 23% |
|
| EPS (5yr) | (10.2%) | 15.9% | 21 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.6%) | (15.6%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | na | 1 | |
| Current EPS | ($0.380) | $0.110 | ($1.520) | |
| Month Ago EPS | ($0.375) | $0.050 | ($1.310) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.375) | $0.050 | ($1.310) | |
| Year/Year Chg | 5.6% | (102.4%) | (92.8%) | |
| Financials | PRTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $55 | $37 | 21% |
|
| Net Income (TTM) (Mil) | ($44) | ($43) | 17% |
|
| EPS (TTM) | ($0.824) | ($1.500) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($60) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $169 | $190 | 25% |
|
| Valuation | PRTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.77 | 2.84 | 45% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PRTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (19.1%) | 66.9% | 3% |
|
| Net Margin | (80.7%) | (74.2%) | 9% |
|
| ROA | (12.5%) | (47.7%) | 24% |
|
| ROE | (14.4%) | (55.0%) | 26% |
|
| Liabilities to Assets | 5.2% | 29.8% | 2% |
|
| F-Score | 6 | 3 | 67% |
|
Prothena Corporation plc did not pass any screens on 9/4/2026.
